Replimune Group Inc - Asset Resilience Ratio
Replimune Group Inc (REPL) has an Asset Resilience Ratio of 43.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Replimune Group Inc's Asset Resilience Ratio has changed over time. Check REPL strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Replimune Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see REPL stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $146.19 Million | 43.82% |
| Total Liquid Assets | $146.19 Million | 43.82% |
Asset Resilience Insights
- Very High Liquidity: Replimune Group Inc maintains exceptional liquid asset reserves at 43.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Replimune Group Inc Industry Peers by Asset Resilience Ratio
Compare Replimune Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Replimune Group Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Replimune Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 67.60% | $372.69 Million | $551.33 Million | -3.39pp |
| 2024-03-31 | 70.99% | $346.21 Million | $487.72 Million | +3.43pp |
| 2023-03-31 | 67.55% | $436.80 Million | $646.59 Million | +4.74pp |
| 2022-03-31 | 62.82% | $289.71 Million | $461.19 Million | +8.72pp |
| 2021-03-31 | 54.09% | $293.78 Million | $543.10 Million | +7.51pp |
| 2020-03-31 | 46.59% | $109.06 Million | $234.10 Million | -24.11pp |
| 2019-03-31 | 70.70% | $109.11 Million | $154.33 Million | +3.21pp |
| 2018-03-31 | 67.49% | $43.97 Million | $65.15 Million | -- |
| 2017-03-31 | 0.00% | $0.00 | $22.82 Million | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more